SCVIi002-A

Registration Summary:

A P E C

The cell line is not submitted yet.

(only basic data is shown)

General

Cell Line
hPSCreg name	SCVIi002-A
Cite as:	SCVIi002-A (RRID:CVCL_A5FV)
Cell line type	Human induced pluripotent stem cell (hiPSC)
Similar lines	No similar lines found.
Last update	8th January 2021
User feedback	Written by on No feedback available yet. Login to share your feedback, experiences or results with the research community.
Provider
Generator	Stanford Cardiovascular Institute (SCVI)
External Databases
Cellosaurus	CVCL_A5FV
Wikidata	Q107116870
General Information
Publications	Liu L et al. Generation of two heterozygous MYBPC3 mutation-carrying human iPSC lines, SCVIi001-A and SCVIi002-A, for modeling hypertrophic cardiomyopathy. Stem cell research. 2021 May;53:102279. Mondéjar-Parreño G et al. Generation of three heterozygous KCNH2 mutation-carrying human induced pluripotent stem cell lines for modeling LQT2 syndrome. Stem cell research. 2021 Jul;54:102402. Caudal A et al. Generation of human induced pluripotent stem cell lines carrying heterozygous PLN mutation from dilated cardiomyopathy patients. Stem cell research. 2022 Aug;63:102855. Zeng W et al. Generation of two induced pluripotent stem cell lines from spinal muscular atrophy type 1 patients carrying no functional copies of SMN1 gene. Stem cell research. 2023 Jun;69:103095. Zhu W et al. Generation of two induced pluripotent stem cell lines from patients with Down syndrome. Stem cell research. 2023 Oct;72:103204. Karakan MÇ et al. Geometry and length control of 3D engineered heart tissues using direct laser writing. Lab on a chip. 2024 Mar 12;24(6):1685-1701. Kathirgamanathan Abiramee et al. Preventing Atrial Fibrillation in Hypertrophic Cardiomyopathy using Angiotensin-Converting Enzyme (ACE) Inhibitors and Angiotensin Receptor Blockers (ARBs). Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal. 2024-03-15.

hIPSC Derivation

General